|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM352254610 |
| 003 |
DE-627 |
| 005 |
20231226053309.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202208923
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1174.xml
|
| 035 |
|
|
|a (DE-627)NLM352254610
|
| 035 |
|
|
|a (NLM)36715052
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Li, Yuanke
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2023
|
| 500 |
|
|
|a Date Revised 30.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Despite the promise in whole-tumor cell vaccines, a key challenge is to overcome the lack of costimulatory signals. Here, agonistic-antibody-boosted tumor cell nanovaccines are reported by genetically engineered antibody-anchored membrane (AAM) technology, capable of effectively activating costimulatory pathways. Specifically, the AAM can be stably constructed following genetic engineering of tumor cell membranes with anti-CD40 single chain variable fragment (scFv), an agonistic antibody to induce costimulatory signals. The nanovaccines are versatilely designed and obtained based on the anti-CD40 scFv-anchored membrane and nanotechnology. Following vaccination, the anti-CD40 scFv-anchored membrane nanovaccine (Nano-AAM/CD40) significantly facilitates dendritic cell maturation in CD40-humanized transgenic mice and subsequent adaptive immune responses. Compared to membrane-based nanovaccines alone, the enhanced antitumor efficacy in both "hot" and "cold" tumor models of the Nano-AAM/CD40 demonstrates the importance of agonistic antibodies in development of tumor-cell-based vaccines. To expand the design of nanovaccines, further incorporation of cell lysates into the Nano-AAM/CD40 to conceptually construct tumor cell-like nanovaccines results in boosted immune responses and improved antitumor efficacy against malignant tumors inoculated into CD40-humanized transgenic mice. Overall, this genetically engineered AAM technology provides a versatile design of nanovaccines by incorporation of tumor-cell-based components and agonistic antibodies of costimulatory immune checkpoints
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a agonistic antibodies
|
| 650 |
|
4 |
|a cell membranes
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a nanovaccines
|
| 650 |
|
4 |
|a tumor
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a CD40 Antigens
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Haoqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ruikun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Ruonan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Mingsheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xiangyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Zhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wan, Yajuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhuang, Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Hongkai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Xinglu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 13 vom: 30. März, Seite e2208923
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:13
|g day:30
|g month:03
|g pages:e2208923
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202208923
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 13
|b 30
|c 03
|h e2208923
|